Fibroblast growth factor (FGF), particularly basic FGF (bFGF or FGF-2), has scientific validation for its use in supporting the healing of abrasions and other skin wounds. Multiple preclinical and clinical studies have demonstrated that FGF plays a significant role in the wound healing process by stimulating the proliferation and migration of fibroblasts, keratinocytes, and endothelial cells. These activities are essential for tissue repair, re-epithelialization, and angiogenesis.

Randomized controlled trials and observational studies, particularly from East Asia, have documented the efficacy of topical bFGF in the treatment of skin abrasions, burns, and chronic ulcers. For instance, studies published in the Journal of Dermatological Treatment and Burns have shown that topical application of bFGF accelerates wound closure, enhances granulation tissue formation, and improves the quality of healing compared to standard treatments. The use of recombinant human bFGF spray is an approved and common clinical practice for skin wounds in countries like China and Japan.

However, while the evidence is strong and consistent, most of the higher-quality studies originate from specific regions, and widespread regulatory approval outside East Asia is limited. Nevertheless, the scientific rationale and the clinical data available support the use of FGF in promoting the healing of abrasions, giving it a high evidential rating.